Axcella Health Inc. (NASDAQ:AXLA) – Stock analysts at Wedbush issued their FY2026 earnings per share (EPS) estimates for shares of Axcella Health in a research report issued to clients and investors on Wednesday, January 12th. Wedbush analyst L. Moussatos expects that the company will post earnings of ($3.83) per share for the year.
Axcella Health (NASDAQ:AXLA) last released its quarterly earnings results on Wednesday, November 10th. The company reported ($0.41) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.45) by $0.04.
AXLA opened at $1.82 on Thursday. The company has a market capitalization of $70.83 million, a PE ratio of -1.12 and a beta of 1.39. Axcella Health has a 1-year low of $1.80 and a 1-year high of $6.84. The firm’s 50 day simple moving average is $2.58 and its two-hundred day simple moving average is $3.07. The company has a current ratio of 8.72, a quick ratio of 8.72 and a debt-to-equity ratio of 0.70.
Large investors have recently modified their holdings of the business. Ergoteles LLC purchased a new position in shares of Axcella Health in the 2nd quarter worth $257,000. Edgewood Management LLC purchased a new position in shares of Axcella Health in the 2nd quarter worth $100,000. Geode Capital Management LLC grew its stake in shares of Axcella Health by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 140,497 shares of the company’s stock worth $418,000 after buying an additional 3,614 shares in the last quarter. Millennium Management LLC grew its stake in shares of Axcella Health by 579.6% in the 2nd quarter. Millennium Management LLC now owns 92,688 shares of the company’s stock worth $372,000 after buying an additional 79,049 shares in the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Axcella Health by 31.4% in the 2nd quarter. Marshall Wace LLP now owns 72,422 shares of the company’s stock worth $290,000 after buying an additional 17,287 shares in the last quarter. 61.75% of the stock is owned by institutional investors and hedge funds.
Axcella Health Company Profile
Axcella Health, Inc is a biotechnology company. It engages in the research and development of treatment for diseases and improve health using endogenous metabolic modulator, or EMM, and compositions. Its product pipeline includes AXA1665, for the reduction in risk of recurrent overt hepatic encephalopathy; and AXA1125, for non-alcoholic steatohepatitis.
Further Reading: How can you know how many shares are floating?
Receive News & Ratings for Axcella Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axcella Health and related companies with MarketBeat.com's FREE daily email newsletter.